MedPath

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Pyronaridine-Artesunate
Drug: Placebo
Registration Number
NCT04475107
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Brief Summary

This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
113
Inclusion Criteria
  1. Age ≥19 years at the time of signing Informed Consent Form
  2. Body weight ≥45 kg at screening
  3. Laboratory (rRT-PCR) confirmed infection with SARS-CoV-2 by testing specimens from upper airway (i.e. nasopharyngeal and oropharyngeal swab) or lower airway (i.e. sputum) within 96 hours of randomization
  4. Oxygen saturation(SpO2) > 94% at randomization, in room air condition
  5. Willing and able to provide informed consent
Exclusion Criteria
  1. Diagnosed with severe pneumonia

  2. Patients with clinically significant cardiovascular disease (including arrhythmia, QTc interval prolongation)

  3. Patients with clinically significant anemia (Hemoglobin <8.0 g/dL)

  4. Patient with known allergic reaction or contraindication to any of the investigational medicinal product (pyronaridine tetraphosphate, artesunate)

  5. Patients with known history of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.

  6. Patients with the gastrointestinal disease and surgery to affect the absorption, distribution, metabolism and excretion of the drug, active gastritis, gastrointestinal tract / rectal bleeding, gastric ulcer, pancreatitis abnormalities (except simple appendectomy or hernia surgery)

  7. Patients who received antiviral drugs that is intended to treat COVID-19, within 28 days prior to screening evaluation (can be enrolled into the study, if the patient has gone through a sufficient wash-out period)

  8. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2)

  9. Patients with known severe liver disease (i.e. ALT or AST>5 times upper limit, nausea, abdominal pain associated with jaundice or Child-Pugh stage B or C)

  10. Viral disease (HIV, HBV, HCV, etc.) other than COVID-19 that require administration of other antiviral agents

  11. Patients that require ventilation therapy (e.g. non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc.)

  12. Patients with chronic underlying disease (e.g. uncontrolled diabetes mellitus, chronic kidney disease, chronic liver disease, chronic pulmonary disease, chronic cardiovascular disease, blood cancer, cancer patients with cancer treatment, patients taking immunosuppressants), highly obese patients, dialysis patients, and transplant patients that are determined by the Physician, to be not suitable for trial involvement.

  13. Pregnant or lactating women

  14. Male or female of childbearing potential who has plans to become pregnant during the study period and for three months after the clinical study or who is not willing to take appropriate contraceptive measures

    *Hormonal contraception (contraceptive implant, injections, pills, etc.), IUDs, condoms (male) and contraceptive diaphragm or cap (female), sterilization (vasectomy, tubal ligation, etc.)

  15. Participating in another clinical trial currently or within 28 days from signing the informed consent

  16. Patients that are deemed ineligible to participate in the clinical trial by the Investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm APyronaridine-ArtesunatePyramax (Pyronaridine 180mg/ Artesunate 60mg)
Arm BPlaceboPlacebo
Primary Outcome Measures
NameTimeMethod
Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*Day 7

\* Patients who are rRT-PCR negative for COVID-19

Secondary Outcome Measures
NameTimeMethod
Time to achieve normalization of oxygen saturation, post-doseDay 3, 7, 10, 14, 28
Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baselineDay 3, 7, 10, 14
Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baselineDay 3, 7, 10, 14, 28
Time to achieve normalization of body temperature, post-doseDay 3, 7, 10, 14, 28
Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*Day 3, 10, 14

\* Patients who are rRT-PCR negative for COVID-19

Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baselineDay 3, 7, 10, 14, 28
Time to achieve normalization of respiratory rate, post-doseDay 3, 7, 10, 14, 28

Trial Locations

Locations (13)

Korea University Ansan Hospital

🇰🇷

Ansan, Korea, Republic of

Chungnam national University Hospital

🇰🇷

Daejeon, Korea, Republic of

Inha University Hospital

🇰🇷

Incheon, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Hallym University Kangnam Sacred Heart Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Kyungpook National University Hospital

🇰🇷

Seoul, Korea, Republic of

National Medical Center

🇰🇷

Seoul, Korea, Republic of

Sahmyook Medical Center

🇰🇷

Seoul, Korea, Republic of

Seoul Medical Center

🇰🇷

Seoul, Korea, Republic of

Scroll for more (3 remaining)
Korea University Ansan Hospital
🇰🇷Ansan, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.